Revised IPC Statement on COVID-19
This revised statement is based on expert opinion and should be interpreted in the context of local policies and emerging evidence.
Monday, December 19, 2022
Psoriasis News
THE LATEST FROM IPC, INDUSTRY AND OTHERS
Results
Commentary: Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial
Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.
Thursday, December 15, 2022
O Futuro do Tratamento na Psoríase Pustulosa Generalizada
Erupções recorrentes, pele vermelha e dolorosa e pústulas estéreis são as características da psoríase pustulosa generalizada (PPG), uma doença autoinflamatória rara e potencialmente fatal.
Tuesday, December 6, 2022
El Futuro del Tratamiento de la Psoriasis Pustulosa Generalizada
Los brotes recurrentes, la piel dolorosa de color rojo fuego y las pústulas estériles son las características de la psoriasis pustulosa generalizada (GPP), una enfermedad autoinflamatoria rara y potencialmente mortal.
Tuesday, December 6, 2022
The Future of Treatment in Generalized Pustular Psoriasis
Recurrent flares, painful fiery-red skin, and sterile pustules — are the characteristics of Generalized Pustular Psoriasis (GPP), a rare and potentially life-threatening autoinflammatory disease.
Tuesday, December 6, 2022
Acesso a Biológicos na Argentina: Repensando o Tempo para PASI 90
Biológicos e biossimilares criaram muitas novas opções no tratamento da psoríase para pacientes em todo o mundo, mas os pacientes em todo o mundo enfrentam barreiras para adquiri-los. Isso levou o Conselheiro do IPC, Dr. Matias Maskin, a reconsiderar o que o sucesso significa para os pacientes com psoríase.
Wednesday, November 16, 2022
Acceso a los Medicamentos Biológicos en Argentina: Repensando el Tiempo Hasta PASI 90
Los productos biológicos y biosimilares han creado muchas opciones nuevas en el tratamiento de la psoriasis para pacientes de todo el mundo, pero los pacientes de todo el mundo enfrentan barreras para adquirirlos. Esto ha llevado al Dr. Matias Maskin, consejero del IPC, a reconsiderar qué significa el éxito para los pacientes con psoriasis.
Wednesday, November 16, 2022
Access to Biologics in Argentina: Rethinking Time to PASI 90
Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to acquiring them. This has led IPC Councilor Dr. Matias Maskin to reconsider what success means for psoriasis patients.
Wednesday, November 16, 2022
IPC Partners with Scientific Education Support to Create New Psoriasis and Psoriatic Arthritis Hub
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.
Friday, November 11, 2022
Monkeypox Symptoms, Treatment, Prevention, and Impact on Psoriasis Patients
The monkeypox outbreak has had a significant impact all across the globe. Here’s what to know about monkeypox symptoms, treatment, and prevention.
Thursday, November 10, 2022
Focus on Psoriasis: A Report from the European Academy of Dermatology and Venereology 31st Annual Congress (EADV)
The European Academy of Dermatology and Venereology (EADV) organized its 31st congress in Milano, Italy, under the parole “Designing the Future of Dermatology and Venereology.” The event took place from September 7 – 10, 2022, as a hybrid meeting with the option of attending virtually or in person. The following congress report includes fifteen summaries of presentations focusing on psoriasis. You can download the full report or read the summary.
Monday, November 7, 2022
Meet Our Newest Councilors
IPC is pleased to introduce and welcome our five newest Councilors for 2022: Pravit Asawanonda, Sunil Dogra, Benjamin Ehst, Filip Rob, and Tsen-Fang Tsai. These individuals were confirmed by the IPC Board of Directors during the European Academy of Dermatology and Venereology (EADV) Congress in September.
Thursday, November 3, 2022
Subscribe to the IPC Newsletter
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
